LENVIMA is a kinase inhibitor that is indicated: Lenvima (lenvatinib capsules) for oral use Initial U.S. Approval: 2015 Lenvima (lenvatinib) is a prescription medicine used to treat patients with inoperable liver cancer, differentiated thyroid cancer, advanced kidney cancer and thymic cancer.<\/p>\n Disease Indications-Kidney Cancer, Liver Cancer, Thyroid Cancer If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import \u201clenvatinib capsules\u201d based on the information you provide.<\/strong><\/p>\n
\nDifferentiated Thyroid Cancer (DTC)<\/strong>
\n\u2022 For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
\nRenal Cell Carcinoma (RCC)<\/strong>
\n\u2022 In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC).
\n\u2022 In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapy.
\nHepatocellular Carcinoma (HCC)<\/strong>
\n\u2022 For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
\nEndometrial Carcinoma (EC)<\/strong>
\n\u2022 In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.<\/p>\nHow To access lenvatinib capsules?<\/h2>\n
\nTo access lenvatinib capsules sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n","protected":false},"excerpt":{"rendered":"lenvatinib capsules,
\nfor oral use Initial U.S. Approval: 2015<\/h2>\nFacts about lenvatinib capsules<\/h4>\n
\nManufacturer-Eisai Europe Ltd
\nUsage-Oral
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA), Therapeutic Goods Administration (TGA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n